Last reviewed · How we verify

Candesartan and enalapril

Herlev Hospital · FDA-approved active Small molecule Quality 5/100

Candesartan and enalapril is a Small molecule drug developed by Herlev Hospital. It is currently FDA-approved.

At a glance

Generic nameCandesartan and enalapril
SponsorHerlev Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Candesartan and enalapril

What is Candesartan and enalapril?

Candesartan and enalapril is a Small molecule drug developed by Herlev Hospital.

Who makes Candesartan and enalapril?

Candesartan and enalapril is developed and marketed by Herlev Hospital (see full Herlev Hospital pipeline at /company/herlev-hospital).

What development phase is Candesartan and enalapril in?

Candesartan and enalapril is FDA-approved (marketed).

Related